pirodavir ID:1444
| Synonyms: |
| CAS NO : 124436-59-5 |
|
| Molecular Formula: C21H27N3O3 |
| Molecular Weight: 369.46 |
| Purity: 98% min |
| Solubility: In DMSO |
| Storage: -20°C |
Availability and Price
| |
If the item is temporarily out of stock. Please email to sales@betterbiochem.com,we will inform you when we have it in stock. |
| In Stock |
| |
 Order |
Remarks:Description: IC50 Value: Pirodavir inhibits 80 percentage of viruses at 0.064 micrograms/ml(EC80)[2]. pirodavir was one of the most promising capsid-binding compounds to show efficacy in human clinical trials for chemoprophylaxis of the common cold. Susceptibility to hydrolysis precluded its use as an oral agent [1]. in vitro: R-77975's predecessor, R 61837, a substituted phenyl-pyridazinamine, was effective in inhibiting 80% of 100 serotypes tested (EC80) at concentrations above 32 micrograms/ml, pirodavir inhibits the same percentage of viruses at 0.064 micrograms/ml. Pirodavir is also effective in inhibiting 16 enteroviruses, with an EC80 of 1.3 micrograms/ml. Pirodavir acts at an early stage of the viral replication cycle (up to 40 min after infection) and reduces the yield of selected rhinoviruses 1,000- to 100,000-fold in a single round of replication [2]. in vivo: Adults with symptoms of < or = 2 days' duration were randomly assigned to intranasal sprays of pirodavir (2 mg per treatment) or placebo six times daily for 5 days. In people with laboratory-documented rhinovirus colds (53 in the pirodavir group, 55 in the placebo group), no significant differences in the resolution of respiratory symptoms were apparent between the groups. The median duration of illness was 7 days in each group. Similarly, scores for individual symptoms found no differences in favor of pirodavir during or after treatment [3]. Clinical trial: N/A
Quality Control
Quality Control by H-NMR,C-NMR,LC-MS,HPLC. |
|
Related Products
 Others |
